United States: Biologics And Biosimilars: Development With An Eye Towards FDA Approval
Last Updated: February 15 2017


Basil "Bill" J. Lewris

Jennifer H. Roscetti
Linda A. Wadler

Friday, February 17, 2017

10:00 - 11:00 a.m. PST
1:00 - 2:00 p.m. EST

In January 2017, the U.S. Food and Drug Administration (FDA) released a highly anticipated draft guidance detailing the agency's expectations for demonstrating biosimilar interchangeability with a reference product and final guidance on nonproprietary naming of biological products. The interchangeability guidance provided more insight into the evidence required to meet the standard for an interchangeability rating, including the scientific justification for extrapolation from one condition of use to another, the recommended framework for switching studies between the reference product and the proposed interchangeable product, and the considerations for determining when post-marketing data is needed. With billions of dollars at stake, how do the new guidelines affect approved and soon-to-be reviewed biosimilar products? What are the best practices for interfacing with the FDA prior to and during the approval process? How might the Trump administration's policies impact the FDA approval process for biologics, biosimilars, and interchangeables?

The second program of this webinar series expands upon issues impacting biologics and biosimilar development, including FDA regulatory issues and interfacing with the FDA before any applications are filed, decisions concerning the types of evidence that are likely to be required to obtain FDA approval, and the FDA's guidance on naming and labeling of biosimilar products.

  • Considerations in selecting a biologic or biosimilar for development
  • Pre-filing meetings with the FDA, including participation in the Biosimilar Development Program
  • Types of evidence to establish biosimilarity
  • Types of evidence to establish interchangeability
  • Comparison of requirements for reference, biobetter, biosimilar, and interchangeable products
  • Naming and labeling requirements

Register: There is no charge to attend this program. Please register by Thursday, February 16, 2017. Webinar access and dial-in information will be sent upon registration.

Scheduling Conflict? Finnegan records all hosted webinars. To view the recorded program, simply register for the webinar and you will receive an access link shortly after the live program is complete.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Press Releases from this Firm
Recent Content from this Firm
By Hazel Ford
By Sanam Habib
By Sanam Habib
By Clare Cornell
By Sanam Habib
By Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
By Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
By John Paul, Brian Kacedon, Robert MacKichan III
By John Paul, Brian Kacedon, Sean Damon
By John Paul, Brian Kacedon, Cecilia Sanabria
Font Size: